202 related articles for article (PubMed ID: 34887387)
1. Targeting of histone methyltransferase DOT1L plays a dual role in chemosensitization of retinoblastoma cells and enhances the efficacy of chemotherapy.
Mao Y; Sun Y; Wu Z; Zheng J; Zhang J; Zeng J; Lee C; Kim JK
Cell Death Dis; 2021 Dec; 12(12):1141. PubMed ID: 34887387
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the DNA damage response and gene expression by the Dot1L histone methyltransferase and the 53Bp1 tumour suppressor.
FitzGerald J; Moureau S; Drogaris P; O'Connell E; Abshiru N; Verreault A; Thibault P; Grenon M; Lowndes NF
PLoS One; 2011 Feb; 6(2):e14714. PubMed ID: 21383990
[TBL] [Abstract][Full Text] [Related]
3. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
Kari V; Raul SK; Henck JM; Kitz J; Kramer F; Kosinsky RL; Übelmesser N; Mansour WY; Eggert J; Spitzner M; Najafova Z; Bastians H; Grade M; Gaedcke J; Wegwitz F; Johnsen SA
Clin Epigenetics; 2019 Jan; 11(1):4. PubMed ID: 30616689
[TBL] [Abstract][Full Text] [Related]
4. UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis.
Kim JK; Kan G; Mao Y; Wu Z; Tan X; He H; Lee C
Mol Oncol; 2020 Feb; 14(2):329-346. PubMed ID: 31782885
[TBL] [Abstract][Full Text] [Related]
5. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
6. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure.
Jones B; Su H; Bhat A; Lei H; Bajko J; Hevi S; Baltus GA; Kadam S; Zhai H; Valdez R; Gonzalo S; Zhang Y; Li E; Chen T
PLoS Genet; 2008 Sep; 4(9):e1000190. PubMed ID: 18787701
[TBL] [Abstract][Full Text] [Related]
7. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
8. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
[TBL] [Abstract][Full Text] [Related]
9. The DOT1L-MLLT10 complex regulates male fertility and promotes histone removal during spermiogenesis.
Lin H; Cossu IG; Leu NA; Deshpande AJ; Bernt KM; Luo M; Wang PJ
Development; 2023 May; 150(9):. PubMed ID: 37082953
[TBL] [Abstract][Full Text] [Related]
10. The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle.
Kim W; Choi M; Kim JE
Cell Cycle; 2014; 13(5):726-38. PubMed ID: 24526115
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Zhang X; Liu D; Li M; Cao C; Wan D; Xi B; Li W; Tan J; Wang J; Wu Z; Ma D; Gao Q
J Hematol Oncol; 2017 Jan; 10(1):29. PubMed ID: 28114995
[TBL] [Abstract][Full Text] [Related]
12. The diverse functions of Dot1 and H3K79 methylation.
Nguyen AT; Zhang Y
Genes Dev; 2011 Jul; 25(13):1345-58. PubMed ID: 21724828
[TBL] [Abstract][Full Text] [Related]
13. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
14. Targeted disruption of the histone lysine 79 methyltransferase Dot1L in nephron progenitors causes congenital renal dysplasia.
Wang F; Ngo J; Li Y; Liu H; Chen CH; Saifudeen Z; Sequeira-Lopez MLS; El-Dahr SS
Epigenetics; 2021 Nov; 16(11):1235-1250. PubMed ID: 33315499
[TBL] [Abstract][Full Text] [Related]
15. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions.
Ho LL; Sinha A; Verzi M; Bernt KM; Armstrong SA; Shivdasani RA
Mol Cell Biol; 2013 May; 33(9):1735-45. PubMed ID: 23428873
[TBL] [Abstract][Full Text] [Related]
16. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
Anglin JL; Song Y
J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
[TBL] [Abstract][Full Text] [Related]
17. Nullifying epigenetic writer DOT1L attenuates neointimal hyperplasia.
Huang Y; Urabe G; Zhang M; Li J; Ozer HG; Wang B; Kent KC; Guo LW
Atherosclerosis; 2020 Sep; 308():22-31. PubMed ID: 32799103
[TBL] [Abstract][Full Text] [Related]
18. Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases.
Wakeman TP; Wang Q; Feng J; Wang XF
EMBO J; 2012 May; 31(9):2169-81. PubMed ID: 22373577
[TBL] [Abstract][Full Text] [Related]
19. DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation.
Cao K; Ugarenko M; Ozark PA; Wang J; Marshall SA; Rendleman EJ; Liang K; Wang L; Zou L; Smith ER; Yue F; Shilatifard A
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27365-27373. PubMed ID: 33077595
[TBL] [Abstract][Full Text] [Related]
20. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.
Steger DJ; Lefterova MI; Ying L; Stonestrom AJ; Schupp M; Zhuo D; Vakoc AL; Kim JE; Chen J; Lazar MA; Blobel GA; Vakoc CR
Mol Cell Biol; 2008 Apr; 28(8):2825-39. PubMed ID: 18285465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]